BC Week In Review | Mar 23, 2018
Clinical News

Caladrius reports interim Phase II data for Type I diabetes candidate

Caladrius Biosciences Inc. (NASDAQ:CLBS) said recent-onset Type I diabetes candidate CLBS03 was "non-futile as determined by predefined futility criteria for therapeutic effect" in an interim analysis of 55 evaluable patients ages 8-17 in the Phase...
BC Week In Review | Mar 10, 2017
Company News

CIRM funding news

CIRM awarded $32.6 million in grants to fund clinical trials and R&D. Caladrius will receive up to $12.2 million for its ongoing Phase II trial of autologous T regulatory cells ( CLBS03 ) to treat recent-onset Type...
BC Week In Review | Nov 2, 2016
Clinical News

CLBS03: Ph II ongoing

An independent DSMB recommended continuation to the second cohort of the double-blind, placebo-controlled, U.S. Phase II T-Rex trial evaluating single infusions of 2 dose levels of CLBS03 in patients ages 12-17. The decision was based...
BC Week In Review | Apr 4, 2016
Clinical News

Autologous T regulatory cells: Phase II started

Caladrius began the double-blind, placebo-controlled, U.S. Phase II T-Rex Study trial to evaluate single infusions of 2 dose levels of CLBS03 in about 111 patients ages 12-17. The Sanford Research subsidiary of Sanford Health (Sioux...
BC Week In Review | Jan 18, 2016
Clinical News

Eltrapuldencel-T: Phase III discontinued

Caladrius discontinued the double-blind, international Phase III Intus trial comparing 10-20 million subcutaneous NBS20 cells vs. about 10 million subcutaneous autologous peripheral blood mononuclear cells (PBMCs) in about 250 patients. The company said immune checkpoint...
BC Extra | Jan 8, 2016
Clinical News

Caladrius ends CIRM-funded melanoma trial

Caladrius Biosciences Inc. (NASDAQ:CLBS) sank $0.36 (34%) to $0.70 on Thursday after announcing plans to discontinue a Phase III study of CLBS20 as monotherapy to treat metastatic melanoma. The company said immune checkpoint inhibitors have...
BC Week In Review | Aug 4, 2014
Clinical News

Autologous T regulatory cells: Preliminary Phase I data

Preliminary data from an open-label, dose-escalation Phase I trial in 14 Type I diabetics ages 18-45 with a mean duration of disease of 10 months, all of whom retained a baseline level of insulin production,...
Items per page:
1 - 7 of 7